Clinical Trial: Obinutuzumab in Systemic Sclerosis

U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07842523) titled 'Obinutuzumab in Systemic Sclerosis' on Aug. 03.

Brief Summary: The purpose of this study is to determine if obinutuzumab is effective in systemic sclerosis

Study Start Date: Nov., 2026

Study Type: INTERVENTIONAL

Condition: Systemic Sclerosis in Adults

Intervention: DRUG: Obinutuzumab

1000mg of i.v obinutuzumab at D1, D15 and D180

DRUG: Placebo

1000mg of i.v placebo at D1, D15 and D180

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Assistance Publique - Hopitaux de Paris

Disclaimer: Curated by HT Syndication....